Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

NCT02613897
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Withdrawn No phase listed Observational Accepts healthy volunteers

Endometrial Cancer Recurrence in Patients Taking Metformin

NCT05192850
Conditions
Recurrent Endometrial Carcinoma
Interventions
Metformin use
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
York, Pennsylvania
Conditions
Diabetes Mellitus, Type 2
Interventions
ipragliflozin, Metformin, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Birmingham, Alabama • Haleyville, Alabama • Mesa, Arizona + 33 more
Conditions
Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Bryant, Arkansas + 22 more
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

NCT02956044
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin, Metformin, Glimepiride, Sitagliptin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 110 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Diabetes Mellitus Type 2
Interventions
metformin, pioglitazone, placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 68 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
85
States / cities
Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting

NCT00834587
Conditions
Healthy
Interventions
5 mg/500 mg METAGLIP™ Tablets, 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Type 2 Diabetes Mellitus
Interventions
Alogliptin, Metformin, Glipizide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
94
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more
Conditions
Type 2 Diabetes
Interventions
Nateglinide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
28 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide and Metformin Therapy in Overweight Women With PCOS

NCT00344851
Conditions
Polycystic Ovary Syndrome
Interventions
metformin, exenatide or combined (metformin & exenatide )
Drug
Lead sponsor
Metabolic Center of Louisiana Research Foundation
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Phase 2 Interventional Results available

Metformin Prostate Cancer Adjuvant Trial

NCT02176161
Conditions
Prostate Cancer, Prostate Cancer Recurrent
Interventions
Metformin Hydrochloride Extended Release 750mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Mineola, New York
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 84 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
60
States / cities
Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

NCT03655301
Conditions
Healthy Volunteers
Interventions
Copanlisib (Aliqopa, BAY80-6946), Metformin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Completed Phase 2 Interventional Results available

A Study of LY2189102 in Patients With Type 2 Diabetes

NCT00942188
Conditions
Type 2 Diabetes
Interventions
LY2189102, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more
Terminated Phase 2 Interventional Results available

Metformin in Heart Failure Without Diabetes

NCT03331861
Conditions
Heart Failure
Interventions
Metformin hydrochloride, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Not listed No phase listed Observational Accepts healthy volunteers

Sugar Challenge Study

NCT04621656
Conditions
Type 2 Diabetes, Pre-Diabetes, Healthy
Interventions
January Mobile Application (Sugar AI)
Combination Product
Lead sponsor
January, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,022 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Menlo Park, California
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more